A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Zenas BioPharma, Inc. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | - | 50M |
| Net Income | -190M | -157M | -37M |
| EPS | $13.67 | $-11.89 | $-24.25 |
| Free Cash Flow | -159M | -120M | -31M |
| ROIC | -49.2% | -50.2% | -43.0% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.37 | 0.18 | -0.09 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -201M | -164M | -37M |
| Operating Margin | 0.0% | - | -74.3% |
| ROE | -96.7% | -362.0% | - |
| Shares Outstanding | 54M | 13M | 42M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | 50M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -37M | -164M | -201M |
| Op. Margin | -74.3% | N/A | 0.0% |
| Net Income | -37M | -157M | -190M |
| Net Margin | -74.2% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -43.0% | -50.2% | -49.2% |
| ROE | N/A | -362.0% | -96.7% |
| ROA | -54.4% | -71.7% | -59.0% |
| Cash Flow | |||
| Op. Cash Flow | -31M | -120M | -158M |
| Free Cash Flow | -31M | -120M | -159M |
| Owner Earnings | -34M | -131M | -169M |
| CapEx | 17K | 131K | 0 |
| Maint. CapEx | 113K | 137K | 137K |
| Growth CapEx | 0 | 0 | 0 |
| D&A | 113K | 137K | 137K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.5M | 11M | 11M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | -37M | N/A | -218M |
| Cash & Equiv. | N/A | N/A | 291M |
| Long-Term Debt | 20M | N/A | 73M |
| Debt/Equity | -0.09 | 0.18 | 0.37 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | -226M | 312M | 196M |
| Total Assets | 68M | 370M | 322M |
| Total Liabilities | 44M | 58M | 126M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -230M | -387M | -387M |
| Working Capital | 37M | 299M | 299M |
| Current Assets | 60M | 356M | 356M |
| Current Liabilities | 23M | 57M | 57M |
| Per Share Data | |||
| EPS | -24.25 | -11.89 | 13.67 |
| Owner EPS | -0.82 | -9.89 | -3.16 |
| Book Value | -5.40 | 23.67 | 3.66 |
| Cash Flow/Share | -0.73 | -9.06 | -3.54 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 41.8M | 13.2M | 53.7M |
| Valuation | |||
| P/E Ratio | N/A | N/A | 1.6 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 0.4 | 5.8 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | -92.2% | -13.8% |
| Market Cap | N/A | 130M | 1.1B |
| Avg. Price | N/A | 16.17 | 21.34 |
| Year-End Price | N/A | 9.84 | 21.34 |
Zenas BioPharma, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Zenas BioPharma, Inc. trades at 1.6x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range.
Zenas BioPharma, Inc. (ZBIO) has a current P/E ratio of 1.6, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
Zenas BioPharma, Inc. (ZBIO) has a 5-year average return on invested capital (ROIC) of -46.6%. This is below average and may indicate limited pricing power.
Zenas BioPharma, Inc. (ZBIO) has a market capitalization of $1.1B. It is classified as a small-cap stock.
Zenas BioPharma, Inc. (ZBIO) does not currently pay a regular dividend.
Based on historical P/E analysis, Zenas BioPharma, Inc. (ZBIO) appears cheap. The current P/E of 1.6 is 90% below its historical median of 15.0.
Zenas BioPharma, Inc. (ZBIO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Zenas BioPharma, Inc. (ZBIO) generated $-120 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Zenas BioPharma, Inc. (ZBIO) has a debt-to-equity ratio of 0.18. This indicates a conservatively financed balance sheet.
Zenas BioPharma, Inc. (ZBIO) reported earnings per share (EPS) of $-11.89 in its most recent fiscal year.
Zenas BioPharma, Inc. (ZBIO) has a return on equity (ROE) of -362.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Zenas BioPharma, Inc. (ZBIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Zenas BioPharma, Inc. (ZBIO) has a book value per share of $23.67, based on its most recent annual SEC filing.